FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073637966> ?p ?o ?g. }

• W2073637966 endingPage "2755" @default.
• W2073637966 startingPage "2751" @default.
• W2073637966 abstract "ABSTRACT Tefibazumab (Aurexis), a humanized monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A, is under development as adjunctive therapy for serious Staphylococcus aureus infections. Sixty patients with documented S. aureus bacteremia (SAB) were randomized and received either tefibazumab at 20 mg/kg of body weight as a single infusion or a placebo in addition to an antibiotic(s). The primary objective of the study was determining safety and pharmacokinetics. An additional objective was to assess activity by a composite clinical end point (CCE). Baseline characteristics were evenly matched between groups. Seventy percent of infections were healthcare associated, and 57% had an SAB-related complication at baseline. There were no differences between the treatment groups in overall adverse clinical events or alterations in laboratory values. Two patients developed serious adverse events that were at least possibly related to tefibazumab; one hypersensitivity reaction was considered definitely related. The tefibazumab plasma half-life was 18 days. Mean plasma levels were <100 μg/ml by day 14. A CCE occurred in six patients (four placebo and two tefibazumab patients) and included five deaths (four placebo and one tefibazumab patient). Progression in the severity of sepsis occurred in four placebo and no tefibazumab patients. Tefibazumab was well tolerated, with a safety profile similar to those of other monoclonal antibodies. Additional trials are warranted to address the dosing range and efficacy of tefibazumab." @default.
• W2073637966 created "2016-06-24" @default.
• W2073637966 creator A5010076935 @default.
• W2073637966 creator A5012804086 @default.
• W2073637966 creator A5030130851 @default.
• W2073637966 creator A5032826942 @default.
• W2073637966 creator A5034402654 @default.
• W2073637966 creator A5036477235 @default.
• W2073637966 creator A5039611876 @default.
• W2073637966 creator A5045500368 @default.
• W2073637966 creator A5049357499 @default.
• W2073637966 creator A5049865970 @default.
• W2073637966 creator A5052775622 @default.
• W2073637966 creator A5053094196 @default.
• W2073637966 creator A5058896809 @default.
• W2073637966 creator A5059168844 @default.
• W2073637966 creator A5062306774 @default.
• W2073637966 creator A5063382165 @default.
• W2073637966 creator A5075457454 @default.
• W2073637966 date "2006-08-01" @default.
• W2073637966 modified "2023-09-23" @default.
• W2073637966 title "Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of <i>Staphylococcus aureus</i> Bacteremia" @default.
• W2073637966 cites W1977802041 @default.
• W2073637966 cites W1982649574 @default.
• W2073637966 cites W1997692689 @default.
• W2073637966 cites W2018825213 @default.
• W2073637966 cites W2031928392 @default.
• W2073637966 cites W2074827635 @default.
• W2073637966 cites W2082441919 @default.
• W2073637966 cites W2087203965 @default.
• W2073637966 cites W2088555149 @default.
• W2073637966 cites W2108023699 @default.
• W2073637966 cites W2114114837 @default.
• W2073637966 cites W2115806935 @default.
• W2073637966 cites W2119245678 @default.
• W2073637966 cites W2134856487 @default.
• W2073637966 cites W2139293110 @default.
• W2073637966 cites W2142004410 @default.
• W2073637966 cites W2155169247 @default.
• W2073637966 cites W2156451821 @default.
• W2073637966 cites W2163392158 @default.
• W2073637966 cites W2167973138 @default.
• W2073637966 cites W2168377135 @default.
• W2073637966 cites W2169198604 @default.
• W2073637966 cites W2171155970 @default.
• W2073637966 cites W2314649741 @default.
• W2073637966 doi "https://doi.org/10.1128/aac.00096-06" @default.
• W2073637966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1538656" @default.
• W2073637966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16870768" @default.
• W2073637966 hasPublicationYear "2006" @default.
• W2073637966 type Work @default.
• W2073637966 sameAs 2073637966 @default.
• W2073637966 citedByCount "131" @default.
• W2073637966 countsByYear W20736379662012 @default.
• W2073637966 countsByYear W20736379662013 @default.
• W2073637966 countsByYear W20736379662014 @default.
• W2073637966 countsByYear W20736379662015 @default.
• W2073637966 countsByYear W20736379662016 @default.
• W2073637966 countsByYear W20736379662017 @default.
• W2073637966 countsByYear W20736379662018 @default.
• W2073637966 countsByYear W20736379662019 @default.
• W2073637966 countsByYear W20736379662020 @default.
• W2073637966 countsByYear W20736379662021 @default.
• W2073637966 countsByYear W20736379662022 @default.
• W2073637966 countsByYear W20736379662023 @default.
• W2073637966 crossrefType "journal-article" @default.
• W2073637966 hasAuthorship W2073637966A5010076935 @default.
• W2073637966 hasAuthorship W2073637966A5012804086 @default.
• W2073637966 hasAuthorship W2073637966A5030130851 @default.
• W2073637966 hasAuthorship W2073637966A5032826942 @default.
• W2073637966 hasAuthorship W2073637966A5034402654 @default.
• W2073637966 hasAuthorship W2073637966A5036477235 @default.
• W2073637966 hasAuthorship W2073637966A5039611876 @default.
• W2073637966 hasAuthorship W2073637966A5045500368 @default.
• W2073637966 hasAuthorship W2073637966A5049357499 @default.
• W2073637966 hasAuthorship W2073637966A5049865970 @default.
• W2073637966 hasAuthorship W2073637966A5052775622 @default.
• W2073637966 hasAuthorship W2073637966A5053094196 @default.
• W2073637966 hasAuthorship W2073637966A5058896809 @default.
• W2073637966 hasAuthorship W2073637966A5059168844 @default.
• W2073637966 hasAuthorship W2073637966A5062306774 @default.
• W2073637966 hasAuthorship W2073637966A5063382165 @default.
• W2073637966 hasAuthorship W2073637966A5075457454 @default.
• W2073637966 hasBestOaLocation W20736379661 @default.
• W2073637966 hasConcept C112705442 @default.
• W2073637966 hasConcept C126322002 @default.
• W2073637966 hasConcept C141071460 @default.
• W2073637966 hasConcept C142724271 @default.
• W2073637966 hasConcept C168563851 @default.
• W2073637966 hasConcept C197934379 @default.
• W2073637966 hasConcept C203092338 @default.
• W2073637966 hasConcept C204787440 @default.
• W2073637966 hasConcept C27081682 @default.
• W2073637966 hasConcept C2777288759 @default.
• W2073637966 hasConcept C2778384902 @default.
• W2073637966 hasConcept C2779443120 @default.
• W2073637966 hasConcept C2779489039 @default.
• W2073637966 hasConcept C501593827 @default.

• next